Gadoterate Meglumine

Summary

Gadoterate Meglumine (CHEMBL2219415) is an approved small molecule; indicated across 3 conditions including brain neoplasm and central nervous system disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 3 conditions
• Clinical trials: 24

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2219415
Name	Gadoterate Meglumine
Type	Small molecule
Max phase	4

Also known as: Dotarem, Gadolinium-dota meglumine, Gadoterate meglumine, Gd-dota meglumine, Magnescope, Meglumine gadoterate, P 449, P-449, P449, GADOTERATE MEGLUMINE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
brain neoplasm	3	MONDO:0021211	EFO:0003833
central nervous system disorder	3	MONDO:0002602	EFO:0009386
interstitial lung disease	2	MONDO:0015925	EFO:0004244

Clinical trials

Total trials: 24.

Phase distribution

Phase	Trials
PHASE4	8
PHASE3	6
Not specified	6
PHASE2	3
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04373564	PHASE4	RECRUITING	Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
NCT00764387	PHASE4	COMPLETED	Contrast Enhanced MRI of the CNS - Patients With Known Cerebral Neoplastic Lesions.
NCT01026389	PHASE4	COMPLETED	Efficacy Evaluation of Dotarem Compared to Gadovist in the Diagnosis of Peripheral Arterial Disease
NCT01254552	PHASE4	COMPLETED	Assessment With CCTA and MRI in Asymptomatic Patients With Type 2 Diabetes for Detection of Unrecognized Myocardial Scar in Subclinical Coronary Atherosclerosis
NCT01806740	PHASE4	TERMINATED	DCE-MRI Using Dotarem® in Evaluation of Therapeutic Response to Sorafenib in Patients With Advanced Stage HCC
NCT02070380	PHASE4	COMPLETED	Crossover Comparison of MultiHance and Dotarem
NCT02411201	PHASE4	COMPLETED	DOTAREM Pharmacokinetics and Safety Study in Pediatric Subjects Aged < 2 Years
NCT03730051	PHASE4	COMPLETED	Dotarem vs Gadobutrol Contrast for Breast MRI
NCT00980681	PHASE3	TERMINATED	Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time-Of-Flight (TOF)
NCT01010932	PHASE3	COMPLETED	Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)
NCT01012674	PHASE3	COMPLETED	Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)
NCT05915702	PHASE3	COMPLETED	A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems
NCT05915728	PHASE3	COMPLETED	A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems)
NCT06057168	PHASE3	COMPLETED	Performance of Elucirem in DSC-MRI Perfusion of Brain Gliomas
NCT05417776	PHASE2	RECRUITING	Collagen-targeted PET Imaging for Early Interstitial Lung Disease
NCT06532071	PHASE2	RECRUITING	Advanced Imaging for Pulmonary Fibrosis
NCT07572383	PHASE2	RECRUITING	Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis
NCT06600880	PHASE1	NOT_YET_RECRUITING	Neuronavigation-guided FUS-induced BBB Opening in Alzheimer’s Disease Patients and Its Effects on Brain Amyloid and Tau
NCT05937776	Not specified	RECRUITING	Developing a New Metabolic Imaging Approach (aMRI) for Evaluating Neurological Disease in Patients With Gliomas
NCT03000036	Not specified	COMPLETED	Doxorubicin-associated Cardiac Remodeling Followed by CMR in Breast Cancer Patients
NCT03023566	Not specified	COMPLETED	Intra-individual Open-label, Single Center Study to Compare Unenhanced MRI With Dotarem Enhanced MRI
NCT03091803	Not specified	WITHDRAWN	QSM and Regional DCE MRI Permeability Using GOCART Technique
NCT03910114	Not specified	COMPLETED	Gadolinium-Based-Contrast-Agents (GBCA) Enhancement During MR Urography
NCT05199792	Not specified	COMPLETED	Efficacy of Gadoterate Meglumine in Diagnosis of Vascular Diseases Using MRA MRA

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).